Alternative Pediatric Oncology Studies Considered As FDA Plans First Request
Executive Summary
FDA is considering alternatives to traditional efficacy trials in order to expedite the approval of oncology products for pediatric uses, particularly for diseases with histology similar in adult and pediatric populations.
You may also be interested in...
FDA Would Grant Pediatric Exclusivity For Negative Oncology Studies
FDA would grant pediatric exclusivity to sponsors despite negative results in either toxicity or efficacy studies, Oncology Drug Products Division Director Richard Pazdur, MD, told the Oncologic Drugs Advisory Committee March 16.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011